CIK 0001439222 · Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-30 | Jones Cecilia Chief Financial Officer | Sale 10b5-1 | −2,932 | $27.09 | $79K | 37,394 |
| 2025-12-30 | Jones Cecilia Chief Financial Officer | Option exercise · Performance share units 10b5-1 | −6,000 | 0 | ||
| 2025-11-12 | Scadden David Director | Option exercise 10b5-1 | +200 | $18.09 | $4K | 17,803 |
| 2025-11-12 | Scadden David Director | Sale 10b5-1 | −200 | $43.84 | $9K | 17,603 |
| 2025-11-12 | Scadden David Director | Option exercise · Stock options (right to buy) 10b5-1 | −200 | 26,907 | ||
| 2025-11-11 | Gheuens Sarah Chief Medical Officer | Option exercise 10b5-1 | +2,454 | $25.01 | $61K | 64,181 |
| 2025-11-11 | Gheuens Sarah Chief Medical Officer | Sale 10b5-1 | −2,454 | $43.78 | $107K | 61,727 |
| 2025-11-11 | Gheuens Sarah Chief Medical Officer | Option exercise · Stock options (right to buy) 10b5-1 | −2,454 | 26,130 | ||
| 2025-10-30 | Gheuens Sarah Chief Medical Officer | Option exercise 10b5-1 | +200 | $25.01 | $5K | 61,927 |
| 2025-10-30 | Gheuens Sarah Chief Medical Officer | Sale 10b5-1 | −200 | $43.81 | $9K | 61,727 |
| 2025-10-30 | Gheuens Sarah Chief Medical Officer | Option exercise · Stock options (right to buy) 10b5-1 | −200 | 28,584 | ||
| 2025-10-27 | Gheuens Sarah Chief Medical Officer | Option exercise 10b5-1 | +3,302 | $25.01 | $83K | 65,029 |
| 2025-10-27 | Gheuens Sarah Chief Medical Officer | Sale 10b5-1 | −3,302 | $43.92 | $145K | 61,727 |
| 2025-10-27 | Gheuens Sarah Chief Medical Officer | Option exercise · Stock options (right to buy) 10b5-1 | −3,302 | 28,784 | ||
| 2025-10-08 | Scadden David Director | Option exercise 10b5-1 | +200 | $18.09 | $4K | 17,803 |
| 2025-10-08 | Scadden David Director | Sale 10b5-1 | −200 | $41.00 | $8K | 17,603 |
| 2025-10-08 | Scadden David Director | Option exercise · Stock options (right to buy) 10b5-1 | −200 | 27,107 | ||
| 2025-09-30 | Scadden David Director | Option exercise 10b5-1 | +200 | $18.09 | $4K | 17,803 |
| 2025-09-30 | Scadden David Director | Sale 10b5-1 | −200 | $40.00 | $8K | 17,603 |
| 2025-09-30 | Scadden David Director | Option exercise · Stock options (right to buy) 10b5-1 | −200 | 27,307 |
Page 10 of 48 · 941 trades